Literature DB >> 16437706

Fenofibrate-induced liver injury.

Kazufumi Dohmen, Chun Yang Wen, Shinya Nagaoka, Koji Yano, Seigo Abiru, Toshihito Ueki, Atsumasa Komori, Manabu Daikoku, Hiroshi Yatsuhashi, Hiromi Ishibashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16437706      PMCID： PMC4727212          DOI： 10.3748/wjg.v11.i48.7702

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


× No keyword cloud information.
  9 in total

1.  Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.

Authors:  S Nakai; T Masaki; K Kurokohchi; A Deguchi; M Nishioka
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid.

Authors:  T Kurihara; A Niimi; A Maeda; M Shigemoto; K Yamashita
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

3.  Is bezafibrate histologically effective for primary biliary cirrhosis?

Authors:  Koji Yano; Hiroyuki Kato; Shigeki Morita; Osamu Takahara; Hiromi Ishibashi; Ryuji Furukawa
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

4.  Fenofibrate treatment in patients with primary biliary cirrhosis.

Authors:  Hiromasa Ohira; Yukio Sato; Takato Ueno; Michio Sata
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

5.  A novel treatment for refractory primary biliary cirrhosis?

Authors:  S Miyaguchi; H Ebinuma; H Imaeda; Y Nitta; T Watanabe; H Saito; H Ishii
Journal:  Hepatogastroenterology       Date:  2000 Nov-Dec

6.  Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers.

Authors:  Uwe Ritzel; Urs Leonhardt; Martina Näther; Gertrud Schäfer; Victor W Armstrong; Giuliano Ramadori
Journal:  J Hepatol       Date:  2002-04       Impact factor: 25.083

7.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

8.  Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway.

Authors:  A D Edgar; C Tomkiewicz; P Costet; C Legendre; M Aggerbeck; J Bouguet; B Staels; C Guyomard; T Pineau; R Barouki
Journal:  Toxicol Lett       Date:  1998-09-01       Impact factor: 4.372

9.  Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

Authors:  Kazufumi Dohmen; Toshihiko Mizuta; Makoto Nakamuta; Naoya Shimohashi; Hiromi Ishibashi; Kyosuke Yamamoto
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742
  9 in total
  10 in total

Review 1.  Pathogenesis of alcoholic liver disease: the role of nuclear receptors.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2010-05

2.  Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  J Biol Chem       Date:  2009-01-27       Impact factor: 5.157

3.  Identification and Characterization of Fenofibrate-Induced Liver Injury.

Authors:  Jawad Ahmad; Joseph A Odin; Paul H Hayashi; Naga Chalasani; Robert J Fontana; Huiman Barnhart; Elizabeth T Cirulli; David E Kleiner; Jay H Hoofnagle
Journal:  Dig Dis Sci       Date:  2017-11-08       Impact factor: 3.199

4.  Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice.

Authors:  Pei-Li Zhu; Si-Yuan Pan; Shu-Feng Zhou; Yi Zhang; Xiao-Yan Wang; Nan Sun; Zhu-Sheng Chu; Zhi-Ling Yu; Kam-Ming Ko
Journal:  Drug Des Devel Ther       Date:  2015-02-17       Impact factor: 4.162

5.  Effects of fenofibrate on adiponectin expression in retinas of streptozotocin-induced diabetic rats.

Authors:  Ying-Jung Hsu; Lu-Chun Wang; Wei-Shiung Yang; Chung-May Yang; Chang-Hao Yang
Journal:  J Diabetes Res       Date:  2014-12-01       Impact factor: 4.011

6.  Effect of fenofibrate on uric acid level in patients with gout.

Authors:  Ju-Yang Jung; Young Choi; Chang-Hee Suh; Dukyong Yoon; Hyoun-Ah Kim
Journal:  Sci Rep       Date:  2018-11-13       Impact factor: 4.379

7.  Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.

Authors:  Shizhan Ma; Shudong Liu; Qi Wang; Lijuan Chen; Ping Yang; Huihuan Sun
Journal:  J Clin Pharm Ther       Date:  2019-09-13       Impact factor: 2.512

Review 8.  PPARα: A potential therapeutic target of cholestasis.

Authors:  Xiaoyin Ye; Tong Zhang; Han Han
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

9.  Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.

Authors:  Vinod S Hegade; Amardeep Khanna; Lucy J Walker; Lin-Lee Wong; Jessica K Dyson; David E J Jones
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

10.  Peroxisome Proliferator Activator Receptor (PPAR)- γ Ligand, but Not PPAR- α , Ameliorates Cyclophosphamide-Induced Oxidative Stress and Inflammation in Rat Liver.

Authors:  Azza A K El-Sheikh; Rehab A Rifaai
Journal:  PPAR Res       Date:  2014-04-02       Impact factor: 4.964
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.